InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,896.21
(
0.44%
)
US TECH 100
20,037.60
(
0.88%
)
Dow Jones
43,438.37
(
-0.02%
)
Brent Oil
72.75
(
2.89%
)
Bitcoin
92,636.24
(
3.08%
)
Post# of 92948
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Smooth

Send PM Follow Ignore
Followers 42
Posts 4592
Boards Moderated 1
Alias Born 03/02/2007

Smooth

Re: rocky301 post# 32942

Thursday, 08/04/2011 4:32:29 PM

Thursday, August 04, 2011 4:32:29 PM

Post# of 92948
"Both trials are prospective, open-label studies designed to determine the safety and tolerability of hESC-derived RPE cells following sub-retinal transplantation into patients with Stargardt's and dry AMD at 12 months, the studies' primary endpoint."

Will the news that comes out of this first dosing tell us anything about efficacy?

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up